Botox maker sees another jackpot in Latisse, due this month
The company behind Botox sees another hit with the first federally approved drug for growing longer, fuller eyelashes, the New York Times
reports. The $120 monthly price tag for Latisse, based on a glaucoma drug, makes some analysts blink, particularly during recession. “If you think about it in terms...